Workshop on evidence for health policy: burden of disease, Cost-Effectiveness, and health systems (Daftar isi: 1.Expanding the WHO tuberculosis control strategy: rethinking the role active case-finding, C.J.L. Murray; 2. Modeling the impact of global tuberculosis control strategies, ChristopherJ.L. Murray; 3. The decision rules of cost-effectiveness analysis, Goran Karlsson; 4. On the decision relus of cost-effectiveness analysis, Magnus Johannesson; 5. Cost-effectiveness and capital costs, Goran k; 6. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations, Andreas Laupacis; 7. Methods for the economic evaluation of health care programmes, Michael F. Drummond; 8. Cost-effectiveness and cost-benefit analysis of health services: the methodology and its application, A. Griffiths; 9. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies, Frank A. Sloan; 10. Cost-benefit analysis (CBA); 11. Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature, Karen B; 12. The use of conjoint analysis to elicit willingness-to-pay values: proceed with caution?, Julie Ratcliffe; 13. Is there a role for benefit-cost analysis in environmental, health, and safety regulation ?, Kenneth J. Arrow; 14. Reasons and persons, Derek Parfit; 15. Qalys and ethics: a health economist's perspective, Alan Williams; 16. Double jeopardy and the use of QALYs in health care allocation, Peter Singer; 17. Double jeopardy, the equal value of lives and the veil of ignorance: a rejoinder to harris, John McKie; 18. The value of DALY life: problems with ethics and validity of disability adjusted life years, Erik Nord; 19. Public preferences for the allocation of donor liver grafts for transplantation, Julie Ratclife; 20. Distributing scarce livers: the moral reasoning of the general public, Peter A. Ubel; 21. Recognizing bedside rationing: clear cases and tough calls, Peter A. Ubel; 22. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial, Mohammad A. Chaudhary; 23. Reflecting uncertainty in cost-effectiveness analysis, W.G. Manning; 24. Hanling uncertanty in economic evaluation, Andrew Briggs; 25. Probabilistic sensitivity analysis in cost-effectiveness: an application from a study of vaccination against pneumococcal bacteremia in the elderly, William Whang; 26. Estimating uncertainty ranges for cost by the bootstrap procedure combined with probabilistic sensitivity analysis, Joanne Lord; 27. Uncertaintyin the economic evaluation of health care technologies: the role of sensitivity analysis, Andrew Briggs; 28. Building uncertainty into cost-effectiveness rankings portofolio risk-return tradeoffs and implications for decision rules, Bernie J. O'Brien; 29. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania, Eric De Jonghe; 30. Linking measures of health gain to explicit priority setting by an area health service in Australia, David A Cromwell; 31. Using discrete choice modelling in priority setting: an application to clinical service developments, Shelley Farrar; 32. Cost-effectiveness analysis and policy choices: investing in health systems, C.J.L. Murray; 33. A cost-effectiveness model for allocating health sector resources, Christopher Murray; 34. Disease control priorities in developing countries: an overview, Dean T. Jamison; 35. Oregon's medicaid ranking and cost-effectiveness: is there any relationship ?, Tammy O. Tengs; 36. Five-hundred life-saving interventions and their cost-effectiveness, Tammy O. Tengs; 37. Prioritising health services in an era of limits: the Oregon experience, John A Kitzhaber; 38. Priority setting: lessons from Oregon, Jennifer Dixon; 39. Oregon's methods: did cost-effectiveness analysis fail?; 40.